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ISSNObjective: To determine the effect of nonadherence to antiretroviral therapy (ART) on
virologic failure and mortality in naive individuals starting ART.
Design: Prospective observational cohort study.
Methods: Eligible individuals enrolled in the Swiss HIV Cohort Study, started ART
between 2003 and 2012, and provided adherence data on at least one biannual
clinical visit. Adherence was defined as missed doses (none, one, two, or more than
two) and percentage adherence (>95, 90–95, and <90) in the previous 4 weeks.
Inverse probability weighting of marginal structural models was used to estimate the
effect of nonadherence on viral failure (HIV-1 viral load >500 copies/ml) and
mortality.
Results: Of 3150 individuals followed for a median 4.7 years, 480 (15.2%) experienced
viral failure and 104 (3.3%) died, 1155 (36.6%) reported missing one dose, 414 (13.1%)
two doses and, 333 (10.6%) more than two doses of ART. The risk of viral failure
increased with each missed dose (one dose: hazard ratio [HR] 1.15, 95% confidence
interval 0.79–1.67; two doses: 2.15, 1.31–3.53; more than two doses: 5.21, 2.96–
9.18). The risk of death increased with more than two missed doses (HR 4.87, 2.21–
10.73). Missing one to two doses of ART increased the risk of viral failure in those
starting once-daily (HR 1.67, 1.11–2.50) compared with those starting twice-daily
regimens (HR 0.99, 0.64–1.54, interaction P¼0.09). Consistent results were found for
percentage adherence. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
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 2196 AIDS 2015, Vol 29 No 16Conclusion: Self-report of two or more missed doses of ART is associated with an
increased risk of both viral failure and death. A simple adherence question helps identify
patients at risk for negative clinical outcomes and offers opportunities for intervention.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2015, 29:2195–2200Keywords: adherence, antiretroviral therapy, causal modeling, mortality, viral
failureIntroduction
Once started, antiretroviral therapy (ART) is lifelong with
the aims of reducing HIV-related morbidity and mortality
[1–3]. Prevention of nonadherence is of utmost
importance for HIV disease management because
nonadherence increases the risk of virological failure
and thus of HIV transmission [4–7]. The relationship
between nonadherence and progression to AIDS or death
has rarely been investigated, and all but one study [6] used
only standard statistical models to adjust for confounding
[8–10]. Such standard approaches may produce biased
effect estimates because they do not properly adjust for
time-dependent confounding, which occurs when
confounders, predictors of both exposure and outcome,
are also affected by prior exposure. For example, choice of
ART drug class may be related both to (expected)
adherence and mortality risk, and prior adherence may
influence future choice of ART drug class [1,11–13]. We
estimated the relationship between nonadherence and
clinical outcomes among antiretroviral-naive patients
starting ART in the Swiss HIV Cohort Study (SHCS),
using inverse probability weighting of marginal structural
models to adjust for time-dependent confounding.Methods
All antiretroviral-naive SHCS participants with prospec-
tively collected data, who initiated ART between 1 January,
2003, and 1 January, 2012, and completed at least one
SHCS adherence questionnaire (SHCS-AQ) during
follow-up were included [4,14,15]. Outcomes were viral
failure, defined as the first HIV-1 RNAviral load more than
500 copies/ml after either achieving viral suppression (viral
load<50 copies/ml) or being on therapy for longer than 24
weeks, and all-cause mortality. We also considered a cutoff
for viral failure of viral load more than 50 copies/ml. The
SHCS-AQ asks participants howoften they missed a dose of
ART in the previous 4 weeks (none, once a month, once
every 2 weeks, once a week, more than once a week, and
every day). These response categories were converted to
missing none, one, two, or more than two doses of ART in
the last 4 weeks, a more clinically meaningful definition that
has been shown to be associated with viral failure and
development of resistance mutations [4,7]. For compar-
ability across regimens with different dosing frequencies,Copyright © 2015 Wolters Kluwer Hpercentage adherencewas also calculated and categorized as
more than 95%, 90–95%, and 90% or less.
Follow-up started at the date of ART initiation (baseline).
The baseline confounders of the relationship between
nonadherence and clinical outcomes included in the
model are provided in Table 1. Confounders with time
updated information were CD4þ cell count, viral load
(mortality model only), time virally suppressed (viral
failure model only), ART class, and dosing frequency.
Follow-up continued until the outcome was observed,
the individual was lost to follow-up (>12 months since
their last visit), or 1 December, 2013, whichever came
first. As we are most interested in the total effect of
nonadherence, individuals were not censored for
intermediate endpoints, such as treatment discontinu-
ation or switching. Follow-up of participants missing any
time-dependent confounder at baseline started at the first
subsequent visit at which the variable was observed.
Both unweighted and weighted (marginal structural
models [MSMs]) pooled logistic regression models were
developed for viral failure and mortality. In the MSM
models, the analysis is weighted to create a pseudopo-
pulation in which time-dependent confounders (which
lie on the causal pathway) at time t-1 no longer predict
nonadherence at time t allowing for measurement of the
total effect of exposure. Provided that there is no
unmeasured confounding, the parameter of the MSM
estimates the causal effect of nonadherence on viral failure
or mortality (for details see eMethods) [11]. In sensitivity
analyses, we explored replacing nonadherence as the
exposure with the interaction between dosing frequency
and nonadherence (missing no doses, missing one to two
doses on a once-daily [q.d.] regimen, missing one to two
doses on a twice-daily [b.i.d.] regimen, missing more than
two doses on a q.d. regimen, and missing more than two
doses on a b.i.d. regimen) [4].Results
Of 3247 treatment-naive individuals initiating ART
during the study period, 86 (2.6%) never completed the
SHCS-AQ, three (0.1%) had HIV-2 virus, and three
(0.1%) did not have follow-up information. The finalealth, Inc. All rights reserved.
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Table 1. Baseline demographic and clinical characteristics of participants.
Variable Overall Adherenta Nonadherenta
N 3155 1781 (56.5) 1374 (43.6)
Age, median (IQR) 40 (33–46) 40 (34–47) 39 (32–45)
Male gender, n (%) 2394 (75.9) 1413 (79.3) 981 (71.4)
Caucasian, n (%) 2511 (79.6) 1456 (81.8) 1055 (76.8)
Basic educationb, n (%) 683 (22.0) 337 (19.2) 346 (25.7)
Risk group for HIV infection, n (%)
Men having sex with men 1568 (49.7) 1004 (56.4) 564 (41.1)
Heterosexual 1185 (37.6) 606 (34.0) 579 (42.1)
IDU 301 (9.5) 123 (6.9) 178 (13.0)
Other 101 (3.2) 48 (2.7) 53 (3.9)
Past or current IDUc, n (%) 354 (11.2) 150 (8.4) 204 (14.9)
Psychiatric comorbidityd, n (%) 579 (18.4) 320 (18.0) 259 (18.9)
Living alone, n (%) 1301 (42.0) 762 (43.5) 539 (40.1)
Stable partnership, n (%) 1869 (60.5) 1058 (60.5) 811 (60.4)
HIV-1 RNA viral load (copies/ml), n (%)
<50 91 (3.0) 58 (3.4) 33 (2.5)
50–399 193 (6.4) 110 (6.4) 83 (6.3)
400 2743 (90.6) 1539 (90.2) 1204 (91.2)
CD4þ cell count (ml), n (%)
<200 930 (30.7) 482 (28.2) 448 (34.0)
200–349 1266 (41.8) 713 (41.7) 553 (42.0)
350–499 547 (18.1) 334 (19.5) 213 (16.2)
500 286 (9.4) 182 (10.6) 104 (7.9)
Median (IQR) 266 (178–363) 278 (186–375) 255 (168–342)
AIDS, n (%) 349 (11.1) 190 (10.7) 159 (11.6)
ART regimen, n (%)
NNRTI 1414 (44.8) 808 (45.4) 606 (44.1)
Protease inhibitor boosted 67 (2.1) 34 (1.9) 33 (2.4)
Protease inhibitor nonboosted 1509 (47.8) 850 (47.7) 659 (48.0)
Triple nucleoside/other 165 (5.2) 89 (5.0) 76 (5.5)
Regimen backbone, n (%)
ZDV/3TC 610 (19.5) 251 (14.2) 359 (26.5)
ABC/3TC 371 (11.9) 212 (12.0) 159 (11.7)
TDF/3TC 230 (7.4) 85 (4.8) 145 (10.7)
TDF/ETC 1808 (57.9) 1164 (65.8) 644 (47.5)
Other 104 (3.3) 56 (3.2) 48 (3.5)
Dosing frequency, n (%)
Once daily 1957 (62.1) 1215 (68.3) 742 (54.0)
Twice daily 1190 (37.8) 561 (31.6) 629 (45.8)
Thrice daily 4 (0.1) 2 (0.1) 2 (0.2)
Number of other HIV patients seen by physician
Median (IQR) 24 (11–69) 26 (11–76) 22 (11–62)
Year of ART initiation, n (%)
2003–2004 472 (15.0) 152 (8.5) 320 (23.3)
2005–2006 511 (16.2) 217 (12.2) 294 (21.4)
2007–2008 706 (22.4) 381 (21.4) 325 (23.7)
2009–2010 881 (27.9) 572 (32.1) 309 (22.5)
2011–2012 585 (18.5) 459 (25.8) 126 (9.2)
Time since HIV diagnosis (years), median (IQR) 1.7 (0.2–4.7) 1.4 (0.1–4.3) 2.1 (0.2–5.1)
ABC/3TC, abacavir/lamivudine; ART, antiretroviral therapy; ZDV/3TC, zidovudine/lamivudine; ETC, emtricitabine; IDU, injecting drug use; IQR,
interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitors; TDF/3TC, tenofovir/lamivudine .
aNonadherent individuals are those reporting any missed doses throughout the follow-up period.
b9 years of mandatory schooling or less.
cEither IDU transmission group or report of use of injecting drugs.
dPsychiatric morbidity is defined as receiving psychiatric treatment, diagnosis of depression, or taking antidepressants.dataset included 3155 individuals with 15 020 person-
years of observation followed for a median 4.7 years
(interquartile range: 2.9–6.9) and completing a median of
nine questionnaires (interquartile range: 5–15). By the
end of follow-up, 1155 (36.6%) individuals had reported
missing one dose, 414 (13.1%) two doses, 333 (10.6%)
more than two doses of ART, 601 (19.0%) 95% or less,
and 387 (12.3%) 90% or less adherence on at least one
occasion. There were 361 (11.4%) individuals lost to
follow-up and 104 died (crude mortality rate ratio 6.57, Copyright © 2015 Wolters Kluwe95% confidence interval [CI]: 5.42–7.97/1000 person-
years). For the outcome of viral failure, an additional 174
individuals were excluded because of the absence of
follow-up RNA. Of the eligible 2981 individuals, 220
(7.4%) individuals were lost to follow-up and 480 (16.1%)
and 1234 (41.4%) experienced viral failure with a
threshold of 500 and 50 copies/ml, respectively.
Patient characteristics are shown in Table 1. Patients
differed in baseline characteristics according to theirr Health, Inc. All rights reserved.
2198 AIDS 2015, Vol 29 No 16adherence. Individuals who reported missing at least
one dose of ART on at least one occasion were more
likely to be women, from the heterosexual or injecting
drug use transmission group, and initiated ART in
earlier years on a b.i.d. regimen without a tenofovir
backbone (Table 1).
Results from regression models were consistent across all
definitions of nonadherence and viral failure. Compared
with no missed doses, the adjusted but unweighted
estimate of the risk of viral failure for missing one dose of
ART was 1.13 (95% CI: 0.78–1.64), missing two doses
was 2.27 (95% CI: 1.39–3.73), and missing more than
two doses was 5.19 (95% CI: 3.21–8.41) (Table 2). The
corresponding estimates from the MSM were similar with
a hazard of 1.15 (95% CI: 0.79–1.67) for missing one
dose, 2.15 (95% CI: 1.31–3.53) for missing two doses,
and 5.21 (95% CI: 2.96–9.18) for missing more than two
doses. When viral failure was defined as HIV-1 RNA
more than 50 copies/ml, the effect of missing only one
dose of ART was now significantly associated with viral
failure in both unweighted and weighted models (hazard
ratio [HR] 1.37, 95% CI: 1.08–1.74 and HR 1.49, 95%
CI: 1.17–1.90, respectively). The MSM models for
percentage adherence were comparable with a significant
increased risk in viral failure for those taking less than 95%
of medication (90–95% HR 1.93, 95% CI: 1.03–3.64;
90% HR 6.47, 95% CI: 3.94–10.63). Copyright © 2015 Wolters Kluwer H
Table 2. Models for the effect of nonadherence to antiretroviral therapy
V
>50copies/ml
HR (95% CI)
Unweighted estimatesb
Missed doses
Missing no doses Reference
Missing one dose 1.37 (1.08–1.74)
Missing two doses 1.86 (1.26–2.75)
Missing more than two doses 3.80 (2.49–5.80)
Percentage adherence
>95% Reference
90–95% 1.45 (0.88–2.40)
<90% 5.00 (3.30–7.57)
Stabilized weighted estimatesc
Missed doses
Missing no doses Reference
Missing one dose 1.49 (1.17–1.90)
Missing two doses 1.96 (1.29–2.99)
Missing more than two doses 4.82 (2.60–8.90)
Percentage adherence
>95% Reference
90–95% 1.56 (0.93–2.63)
<90% 7.79 (4.65–13.04)
ART, antiretroviral therapy; CI, confidence intervals; HR, hazard ratio; IDU
aViral failure was defined as the first HIV-1 RNA viral load above the spe
<50copies/ml) or being on therapy for longer than 24 weeks.
bModels include nonadherence, past nonadherence, and a time-varying in
education, Caucasian ethnicity, living alone, having a stable partnership, psy
backbone of regimen, dosing frequency, time period of ART initiation, time s
varying covariates (ART class, dosing frequency, CD4, RNA [mortality mode
[viral failure model only]).
cThese models are estimated using MSMs. The time-varying covariates areIn mortality models, the unweighted adjusted mortality
HR for missing one dose of ART was 1.31 (95% CI:
0.62–2.75), for missing two doses 1.06 (95% CI: 0.25–
4.41), and for missing more than two doses 2.89 (95% CI:
1.13–7.41) compared with no missed doses (Table 2).
The mortality HRs from the MSM estimated stronger
effects of nonadherence: missing one dose 1.32 (95% CI:
0.42–4.17), missing two doses 1.26 (95% CI: 0.36–4.44),
and missing more than two doses 4.87 (95% CI: 2.21–
10.73). The estimates from MSM model with percentage
adherence were similar (Table 2). At baseline, 62.8% of
naive individuals started ART on a q.d. regimen and
37.2% on a b.i.d. regimen. The number of individuals
initiating a q.d. regimen increased from 12.4% in 2003 to
84.6% in 2012. We found evidence of an interaction
between dosing frequency and missed doses in MSM
models; the effect of missed doses on viral failure was
different in those missing one to two doses on q.d. and
b.i.d. regimens. Compared with missing no doses on
either a q.d. or b.i.d. regimen, the effect of missing one to
two doses was 1.67 (95% CI: 1.11–2.50) and 0.99 (95%
CI: 0.64–1.54) on a q.d. and b.i.d. regimen, respectively,
(P value for interaction¼ 0.09), and missing more than
two doses was 5.62 (95% CI: 2.98–10.62) and 4.05 (95%
CI: 1.08–1.46) in those on q.d. and b.i.d. regimens (P
value for interaction¼ 0.33), respectively. Models with
percentage adherence yielded similar results (90–95%:
q.d. 4.30 [1.62–11.42], b.i.d. 0.69 [0.16–2.94]; <90%:ealth, Inc. All rights reserved.
on clinical outcomes.
iral failurea Death
>500 copies/ml
HR (95% CI) HR (95% CI)
Reference Reference
1.13 (0.78–1.64) 1.31 (0.62–2.75)
2.27 (1.39–3.73) 1.06 (0.25–4.41)
5.19 (3.21–8.41) 2.89 (1.13–7.41)
Reference Reference
2.07 (1.10–3.87) 2.56 (0.79–8.30)
6.94 (4.44–10.86) 2.59 (0.85–7.86)
Reference Reference
1.15 (0.79–1.67) 1.32 (0.42–4.17)
2.15 (1.31–3.53) 1.26 (0.36–4.44)
5.21 (2.96–9.18) 4.87 (2.21–10.73)
Reference Reference
1.93 (1.03–3.64) 1.85 (0.55–6.23)
6.47 (3.94–10.63) 4.45 (1.99–9.93)
, injecting drug use.
cified threshhold after either achieving viral suppression (viral load
tercept as well as the following baseline covariates (age, sex, basic
chiatric comorbidity, IDU, AIDS, CD4, HIV-1 viral load, class of ART,
inceHIV diagnosis, and experience of the treating physician) and time-
l only], and length of time an individual maintained viral suppression
only included in the model for the weights.
Impact of adherence to antiretroviral drugs Glass et al. 2199q.d. 9.01 [4.02–20.21], b.i.d. 4.38 [1.78–10.74]). There
were not enough events to explore the interaction in
mortality models.Discussion
Nonadherence, as assessed by self-report, was found to
increase the risk of viral failure and mortality in models
adjusting for both time-independent and time-updated
variables as well as past adherence. Each additional missed
dose was associated with an increase in the risk of viral
failure exhibiting a clear dose–response relationship, and
missing more than two doses of ART had an
approximately five-fold increase in the hazard of viral
failure and death. Simplification to q.d. regimens can lead
to better adherence but our findings indicate an increased
risk of viral failure on q.d. compared with b.i.d. regimens
in the presence of nonadherence.
It is difficult to compare our results with previous studies
because of different measurement methods and defi-
nitions of nonadherence. Our effect estimates are
somewhat higher than those reported in earlier studies
likely because of proper adjustment for time-dependent
confounding (providing the total effect of nonadherence)
and less precise because of the lower number of events in
our study, particularly deaths [8,9,16].
The present study has several strengths and limitations.
Like all observational studies, the effect estimates have a
causal interpretation only if there is no unmeasured
confounding. The strength of the study was our ability to
include many important confounders of the relationship
between adherence and clinical outcomes (such as
psychosocial factors); however, unmeasured confounders,
such as lifestyle and health-seeking behaviors, may bias
our estimates. We further strengthened the study by doing
extensive sensitivity analyses, which verified the robust-
ness of our estimates and did not change the substantive
conclusions from the analysis.
Another limitation of this study is the use of self-reported
adherence, which is known to overestimate adherence
compared with objective measures [17,18]. Investigation
of nonadherence by physicians during consultations may
lead to an overestimate of adherence because of poor
recall or fear to disclose undesirable behavior. Despite this
potential bias, this simple adherence question had the
sensitivity to detect different effects of missing doses on
different viral load thresholds. Self-report is the most
likely candidate for widespread use in daily clinical
practice because of its many advantages over other
measurement methods, such as low cost and ease
of administration.
The SHCS is a long-standing and well described cohort
that collects a variety of information longitudinally in a Copyright © 2015 Wolters Kluwediverse population, including understudied groups such
as heterosexuals, drug users, and women, increasing the
generalizability of the results. Regardless, additional
validation of these findings in other patient populations
and cultural settings is warranted.
Over an average follow-up of 5 years, one out of 10
patients reported having missed more than two doses of
ART during the last 4 weeks. Regular investigation of
adherence at each clinic visit is therefore crucial and
reports of nonadherence should alert physicians to not
only provide adherence support but to explore potential
underlying reasons for the lack of adherence. This
opportunity for early and appropriate intervention could
lead to a reduction in drug failure and resistance. The
sensitivity of this simple adherence question to predict
poor clinical outcomes has wide implications and should
be considered for use in resource-limited settings where
viral load often cannot be measured.Acknowledgements
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